World Health Organization Special Programme of Research, Development, and Research Training in Human Reproduction; Task Force on Long-Acting Systemic Agents for the Regulation of Fertility

[1]  L. Atkinson,et al.  An approach to the analysis of menstrual patterns in the critical evaluation of contraceptives. , 1976, Studies in family planning.

[2]  O. Kiriwat,et al.  Intramuscular depomedroxyprogesterone acetate for contraception. , 1974, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

[3]  E. Kesserü-Koós,et al.  Fertility control with norethindrone enanthate, a long-acting parenteral progestogen. , 1973, Acta Europaea fertilitatis.

[4]  P. C. Schwallie,et al.  Contraceptive use--efficacy study utilizing medroxyprogesterone acetate administered as an intramuscular injection once every 90 days. , 1973, Fertility and sterility.

[5]  J. Goldzieher,et al.  Injectable contraceptives in family planning - clinical experience in 14958 cycles. , 1973 .

[6]  J. Zañartu,et al.  Long‐acting Injectable Progestogens in Human Fertility Control , 1972 .

[7]  M. Karim,et al.  The long-term use of injectable norethisterone enanthate as a contraceptive. , 1972, Contraception.

[8]  S. Chinnatamby.  A Comparison of the Long‐Acting Contraceptive Agents Norethisterone Oenanthate and Medroxyprogesterone Acetate , 1971, The Australian & New Zealand journal of obstetrics & gynaecology.

[9]  J. Elliot,et al.  Present status of injectable contraceptives: results of seven-years study. , 1970, Fertility and sterility.

[10]  A. Treloar,et al.  Variation of the human menstrual cycle through reproductive life. , 1967, International journal of fertility.